A First-in-human (FIH), Multicenter, Open-Label, Phase I Study of PTX-912 in Patients With Locally Advanced/Metastatic Solid Tumors

Solid Tumor Clinical Trial

Official title:

A First-in-human (FIH), Multicenter, Open-Label, Phase Ia (Dose Escalation)/Phase Ib (Dose Expansion) Study of PTX-912 in Patients With Locally Advanced/Metastatic Solid Tumors

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06190886
• Other study ID #: PTX-912-001
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: April 27, 2024
• Est. completion date: July 24, 2026

Study information

• Verified date: January 2024
• Source: Proviva Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of PTX-912 in patients with locally advanced or metastatic solid tumors. To evaluate the PK and immunogenicity profile of PTX-912. To evaluate the preliminary anti-tumor activity of PTX-912.

Participants will be treated with PTX-912 via iv infusion, every 2 weeks until progression of disease, unacceptable toxicity, or 12 months of total study therapy.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 26
• Est. completion date: July 24, 2026
• Est. primary completion date: May 14, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Willing and able to provide signed and dated informed consent prior to any study-related procedures and willing and able to comply with all study procedures.

2. Male and Female patients age = 18 years on day of signing informed consent.

3. Willing to comply with all protocol-required visits, assessments, and procedures.

4. Patients with locally advanced or metastatic solid tumors who have had disease progression on all available standard of care or for whom no reasonable standard of care exists that would confer clinical benefit.

5. Recovery from all toxicities associated with prior therapy to acceptable baseline status (for laboratory toxicities, see limits for inclusion). NCI CTCAE v5.0 Grade 0 or 1, except for toxicities not considered a safety risk (e.g., alopecia or vitiligo).

6. Measurable disease per RECIST v1.1.

7. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 with no deterioration during Screening.

8. Adequate bone marrow and organ function, defined by the following laboratory results obtained within 14 days before first dose of study drug.

9. Patients with recent major surgery must have adequately recovered with no ongoing complications from the surgery prior to receiving study treatment.

10. Willingness to adhere to the study treatment-specific contraception requirements.

11. Estimated life expectancy of 3 months (12 weeks) or greater as determined by Investigator.

Exclusion Criteria:

1. Has a diagnosis of immunodeficiency.

2. Has an active infection requiring systemic therapy within 4 weeks prior to study treatment.

3. History of or known intolerance, significant hypersensitivity, or anaphylaxis to any components of PTX-912 or any of the excipients.

4. Unresolved toxicities from prior systemic therapy greater than NCI CTCAE grade 1 at time of first dose, except alopecia, vitiligo, and grade 2 neuropathy due to prior chemotherapy.

5. Experienced clinically significant immune-related toxicity from prior immunotherapy that in the opinion of the investigator would preclude protocol therapy or would make the patient inappropriate for the study.

6. Major surgery within 30 days prior to first dose of study drug (with the below exceptions), or anticipation of major surgery during study treatment.

7. Active autoimmune disease requiring systemic treatment within the past 3 months or have a documented history of clinically severe autoimmune disease that requires systemic steroids or immunosuppressive agents.

8. Uncontrolled diabetes mellitus or other uncontrolled immune-related endocrinopathies in the opinion of the investigator.

9. Primary central nervous system (CNS) disease or leptomeningeal disease.

10. Impaired cardiovascular function or clinically significant cardiovascular disease.

11. Abnormal pulmonary function within the previous 6 months, including history of pneumonitis, active pneumonitis, interstitial lung disease requiring the use of steroids, idiopathic pulmonary fibrosis, active pleural effusion, severe dyspnea at rest or requiring supplementary oxygen therapy.

12. History of allogenic, bone marrow, or solid organ transplants.

13. Received a live-virus vaccination =14 days prior to first dose of study drug (seasonal flu and other inactivated vaccines that do not contain live virus are permitted).

14. Clinically significant bleeding within 2 weeks prior to first dose of study drug dy.

15. Pregnant or breast-feeding women or expecting to conceive within the projected duration of the trial, starting with the screening visit through 3 months after the last dose of study drug.

Related Conditions & MeSH terms

• Advanced Cancer
• Metastatic Cancer
• Neoplasm Metastasis
• Solid Tumor

Intervention

Drug:
• PTX-912
biologics

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Proviva Therapeutics, Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	DLTs (dose limiting toxicity)	Frequency, severity, and duration of treatment-emergent adverse events (TEAEs) and laboratory abnormalities for all dose groups according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0; except for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) which will be graded according to American Society for Transplantation and Cellular Therapy (ASTCT) Consensus Grading.	within 28 days